Journal article
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease
Abstract
BACKGROUND AND GOALS: The role of early proactive therapeutic drug level monitoring for anti-tumor necrosis factor therapies is unclear. We aimed to determine whether a week 2 serum trough level in patients with inflammatory bowel disease (IBD) using adalimumab may predict clinical outcomes.
MATERIALS AND METHODS: This was a retrospective study of consecutive IBD patients with a week 2 serum adalimumab level available. Receiver operating …
Authors
Buffone E; Gupta S; Al Ibrahim B; Marshall JK; Halder S; Tse F; Albashir S; Morgan D; Lumb B; Armstrong D
Journal
Journal of Clinical Gastroenterology, Vol. 56, No. 9, pp. 794–797
Publisher
Wolters Kluwer
Publication Date
October 2022
DOI
10.1097/mcg.0000000000001636
ISSN
0192-0790